- Trials with a EudraCT protocol (31)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
31 result(s) found for: Quarantine.
Displaying page 1 of 2.
EudraCT Number: 2020-003887-21 | Sponsor Protocol Number: HVO-CS-005 | Start Date*: 2020-11-03 |
Sponsor Name:hVIVO Services Limited | ||
Full Title: A Phase 2a, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Immunogenicity and Efficacy of A Respiratory Syncytial Virus Vaccine (RSVpreF) in A Virus Challenge Model in H... | ||
Medical condition: Respiratory Syncytial Virus Infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001044-26 | Sponsor Protocol Number: MB05-P-01-20 | Start Date*: 2020-05-12 | |||||||||||
Sponsor Name:mAbxience Research S.L. | |||||||||||||
Full Title: A Double-Blind, Randomised, Placebo-Controlled Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated with Respiratory Syncytial Virus (RSV) | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001107-20 | Sponsor Protocol Number: MDT-637-CP-201 | Start Date*: 2013-08-02 | |||||||||||
Sponsor Name:MicroDose Therapeutx, Inc., a wholly owned subsidiary of Teva Pharmaceuticals Industries, Ltd. | |||||||||||||
Full Title: A Phase 2a Randomised, Double-Blind, Placebo-Controlled Repeat Dose Trial of the Activity of MDT-637 in Healthy Subjects Challenged with RSV-A (Memphis 37b) | |||||||||||||
Medical condition: RSV Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002134-74 | Sponsor Protocol Number: FLU-v004 | Start Date*: 2016-07-27 | |||||||||||
Sponsor Name:PepTcell Limited (trade name SEEK) | |||||||||||||
Full Title: Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model | |||||||||||||
Medical condition: Influenza virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004042-26 | Sponsor Protocol Number: PrEP-CS-002 | Start Date*: 2015-11-17 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Asthmatic Subjects Subsequently Challenged with Human Rhinoviru... | |||||||||||||
Medical condition: Human Rhinovirus (HRV-16) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001714-24 | Sponsor Protocol Number: BTA798-CL2-001 | Start Date*: 2008-06-18 |
Sponsor Name:Biota Scientific Management Pty Ltd | ||
Full Title: A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model | ||
Medical condition: BTA798 is an investigational drug being developed as a potential agent for treatment and prevention of the common cold. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2020-000919-69 | Sponsor Protocol Number: 73249 | Start Date*: 2020-03-17 | |||||||||||
Sponsor Name:University Medical Center | |||||||||||||
Full Title: Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19). | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001888-90 | Sponsor Protocol Number: 20201504 | Start Date*: 2020-04-30 | |||||||||||
Sponsor Name:University of Southern Denmark | |||||||||||||
Full Title: Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic. A randomised controlled multi-center trial. | |||||||||||||
Medical condition: Healthy volunteers, health care workers. Immune system activation after BCG vaccination. Work absenteeism and COVID-19 will be monitored. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004137-21 | Sponsor Protocol Number: 78591.041.21 | Start Date*: 2021-10-28 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Effect of intranasal administration of palivizumab on experimental respiratory syncytial viral infection – a human challenge study | ||
Medical condition: respiratory syncytial virus infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-001282-24 | Sponsor Protocol Number: REVCS002 | Start Date*: 2017-06-21 | |||||||||||
Sponsor Name:ReViral Ltd | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of RV521 Against Respiratory Syncytial Virus infecti... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000854-73 | Sponsor Protocol Number: TCN‐032‐002 | Start Date*: 2012-06-21 | ||||||||||||||||
Sponsor Name:THERACLONE SCIENCES, INC. | ||||||||||||||||||
Full Title: A PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TCN-032 (HUMAN MONOCLONAL ANTIBODY DIRECTED AGAINST THE M2 PROTEIN OF INFLUENZA A VIRUS) IN SUBJECTS CHALLENGED WITH H3N2 INFLUENZA A VIRUS | ||||||||||||||||||
Medical condition: Treatment of severe influenza A virus disease. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-006902-27 | Sponsor Protocol Number: ALN-RSV01-105 | Start Date*: 2007-04-18 | |||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | |||||||||||||
Full Title: A randomized, double-blind, placebo-controlled, parallel-group study to investigate the safety and efficacy of intranasal ALN-RSV01 administered to adult volunteers experimentally inoculated with R... | |||||||||||||
Medical condition: Experimentally induced Respiratory Syncytial Virus infection. The experimental infectious dose has been titrated in a previous study in healthy volunteers. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004036-30 | Sponsor Protocol Number: ALS-8176-502 | Start Date*: 2013-11-29 | |||||||||||
Sponsor Name:Alios BioPharma | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Multiple Doses of Orally Administered ALS-008176 Against Respirator... | |||||||||||||
Medical condition: Respiratory Syncytial Virus (RSV) infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-004296-77 | Sponsor Protocol Number: BTA585-003 | Start Date*: 2016-02-08 |
Sponsor Name:Biota Pharma Europe Limited | ||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Antiviral Activity Against Respiratory Syncytial Virus Infection, and the Pharmacokinetics of Multiple Oral... | ||
Medical condition: Respiratory Syncytial Virus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-002185-39 | Sponsor Protocol Number: CR8020FLZ2002 | Start Date*: 2013-08-30 | |||||||||||
Sponsor Name:Crucell Holland B.V | |||||||||||||
Full Title: Randomised, Double-Blind, Placebo-Controlled, Phase IIa Study in Healthy Volunteers to Evaluate the Protective Efficacy and Safety of CR8020 in an Influenza Challenge Model | |||||||||||||
Medical condition: Influenza | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004612-22 | Sponsor Protocol Number: FP-01.1_CS_04 | Start Date*: 2013-12-24 | |||||||||||
Sponsor Name:Immune Targeting Systems Ltd | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled study to assess the safety, tolerability, efficacy and immunogenicity of an influenza A vaccine (Vaccine FP-01.1) in healthy volunteers following viru... | |||||||||||||
Medical condition: | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002895-26 | Sponsor Protocol Number: PrEP-CS-001 | Start Date*: 2015-09-08 | |||||||||||
Sponsor Name:hVIVO Services Limited | |||||||||||||
Full Title: A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with In... | |||||||||||||
Medical condition: Influenza A/Perth/16/2009(H3N2) Virus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-001878-21 | Sponsor Protocol Number: EDP938-101 | Start Date*: 2018-10-05 | |||||||||||
Sponsor Name:ENANTA Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study To Evaluate The Safety, Pharmacokinetics And Antiviral Activity Of Multiple Doses Of Orally Administered EDP-938 Against Respiratory S... | |||||||||||||
Medical condition: Respiratory Syncytial Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001502-38 | Sponsor Protocol Number: VP-C21-006 | Start Date*: 2020-05-06 | |||||||||||
Sponsor Name:Vicore Pharma AB | |||||||||||||
Full Title: A randomised, double blind, placebo controlled, Phase 2 trial investigating the safety and efficacy of C21 in hospitalised subjects with COVID-19 infection not requiring mechanical ventilation | |||||||||||||
Medical condition: Covid-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010334-21 | Sponsor Protocol Number: Flu002 | Start Date*: 2009-04-17 |
Sponsor Name:Oxford University | ||
Full Title: A phase IIa study to assess the safety and efficacy of a new influenza vaccine candidate MVA-NP+M1 in healthy adults. | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
